• 1
    Jonsson R, Haga HJ, Gordon TP. Sjögren's syndrome. In: KoopmanWJ, editor. Arthritis and allied conditions: a textbook of rheumatology. 14th ed. Philadelphia: Lippincott Williams & Wilkins; 2001. p. 173659.
  • 2
    Manthorpe R, Jacobsson L, Manthorpe T. Overview of classification criteria for SS. In: HommaM, SugaiS, TojoT, MiyasakaN, AkizukiM, editors. Sjögren's syndrome—state of the art: Amsterdam: Kugler; 1999. p. 6972.
  • 3
    Vitali C, Bombardieri S, Jonsson R, Moutsopoulos HM, Alexander EL, Carsons SE, et al, and the European Study Group on Classification Criteria for Sjögren's Syndrome. Classification criteria for Sjögren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis 2002; 61: 5548.
  • 4
    Gordon TP, Bolstad AI, Rischmueller M, Jonsson R, Waterman SA. Autoantibodies in primary Sjögren's syndrome: new insights into mechanisms of autoantibody diversification and disease pathogenesis. Autoimmunity 2001; 34: 12332.
  • 5
    Brayer JB, Cha S, Nagashima H, Yasunari U, Lindberg A, Diggs S, et al. IL-4-dependent effector phase in autoimmune exocrinopathy as defined by the NOD.IL-4-gene knockout mouse model of Sjögren's syndrome. Scand J Immunol 2001; 54: 13340.
  • 6
    Nguyen KH, Brayer J, Cha S, Diggs S, Yasunari U, Hilal G, et al. Evidence for antimuscarinic acetylcholine receptor antibody–mediated secretory dysfunction in NOD mice. Arthritis Rheum 2000; 43: 2297306.
  • 7
    Waterman SA, Gordon TP, Rischmueller M. Inhibitory effects of muscarinic receptor autoantibodies on parasympathetic neurotransmission in Sjögren's syndrome. Arthritis Rheum 2000; 43: 164754.
  • 8
    Reichlin M. Antibodies to Ro and La. Ann Med Interne (Paris) 1998; 149: 3441.
  • 9
    Cavill D, Waterman SA, Gordon TP. Failure to detect antibodies to extracellular loop peptides of the muscarinic M3 receptor in primary Sjögren's syndrome. J Rheumatol 2002; 29: 13424.
  • 10
    Bacman S, Berra A, Sterin-Borda L, Borda E. Muscarinic acetylcholine receptor antibodies as a new marker of dry eye Sjögren syndrome. Invest Ophthalmol Vis Sci 2001; 42: 3217.
  • 11
    Vitali C, Bombardieri S, Moutsopoulos HM, and the European Study Group on Diagnostic Criteria for Sjögren's Syndrome. Assessment of the European classification criteria for Sjögren's syndrome in a series of clinically defined cases: results of a prospective multicentre study. Ann Rheum Dis 1996; 55: 11621.
  • 12
    Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982; 25: 12717.
  • 13
    Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988; 31: 31524.
  • 14
    Hellstrom-Lindahl E, Nordberg A. Muscarinic receptor subtypes in subpopulations of human blood mononuclear cells as analyzed by RT-PCR technique. J Neuroimmunol 1996; 68: 13944.
  • 15
    Konttinen Y, Tensing E, Tornwall J, Kitti U, Ceponis A. Neurogenic factors in the pathogenesis of Sjögren's syndrome. In: EriksssonP, JonssonR, editors. The 100 year anniversary of Henrik Sjögren. Jönköping (Sweden): Hygiea; 1999. p. 805.
  • 16
    Cha S, Peck AB, Humphreys-Beher MG. Progress in understanding autoimmune exocrinopathy using the non-obese diabetic mouse: an update. Crit Rev Oral Biol Med 2002; 13: 516.